14,545 Shares in Ariad Pharmaceuticals Inc. (ARIA) Acquired by Los Angeles Capital Management & Equity Research Inc.
Los Angeles Capital Management & Equity Research Inc. purchased a new position in Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,545 shares of the pharmaceutical company’s stock, valued at approximately $107,000.
Several other institutional investors have also modified their holdings of ARIA. Lebenthal Lisanti Capital Growth LLC acquired a new position in shares of Ariad Pharmaceuticals during the second quarter worth about $421,000. First Trust Advisors LP acquired a new position in shares of Ariad Pharmaceuticals during the second quarter worth about $481,000. Granite Point Capital Management L.P. acquired a new position in shares of Ariad Pharmaceuticals during the second quarter worth about $3,184,000. State Board of Administration of Florida Retirement System increased its position in shares of Ariad Pharmaceuticals by 0.9% in the second quarter. State Board of Administration of Florida Retirement System now owns 137,570 shares of the pharmaceutical company’s stock worth $1,017,000 after buying an additional 1,270 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in shares of Ariad Pharmaceuticals by 18.0% in the second quarter. DekaBank Deutsche Girozentrale now owns 96,200 shares of the pharmaceutical company’s stock worth $718,000 after buying an additional 14,700 shares during the last quarter. 71.99% of the stock is currently owned by institutional investors and hedge funds.
Shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) traded down 1.75% during midday trading on Monday, reaching $13.45. The company’s stock had a trading volume of 2,051,549 shares. Ariad Pharmaceuticals Inc. has a 52 week low of $4.37 and a 52 week high of $14.26. The stock’s market capitalization is $2.59 billion. The company has a 50 day moving average of $11.38 and a 200-day moving average of $8.56.
Ariad Pharmaceuticals (NASDAQ:ARIA) last released its quarterly earnings data on Thursday, July 28th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.70. The firm had revenue of $65.30 million for the quarter, compared to analysts’ expectations of $60.64 million. Ariad Pharmaceuticals’s revenue for the quarter was up 133.0% on a year-over-year basis. During the same period last year, the firm posted ($0.28) earnings per share. Equities research analysts predict that Ariad Pharmaceuticals Inc. will post ($0.09) earnings per share for the current year.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research raised Ariad Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $16.00 price target on the stock in a research report on Wednesday, September 28th. Leerink Swann started coverage on Ariad Pharmaceuticals in a research report on Monday, September 26th. They issued an “outperform” rating on the stock. Cowen and Company reissued an “outperform” rating and issued a $10.00 target price on shares of Ariad Pharmaceuticals in a research report on Sunday, July 31st. Jefferies Group reissued a “buy” rating and issued a $13.00 target price on shares of Ariad Pharmaceuticals in a research report on Friday, July 29th. Finally, Barclays PLC upped their target price on Ariad Pharmaceuticals from $8.00 to $9.00 and gave the company an “underweight” rating in a research report on Friday, July 29th. One research analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $10.13.
In other news, insider Timothy P. Clackson sold 25,000 shares of Ariad Pharmaceuticals stock in a transaction on Friday, August 12th. The shares were sold at an average price of $10.50, for a total transaction of $262,500.00. Following the completion of the sale, the insider now directly owns 273,208 shares of the company’s stock, valued at approximately $2,868,684. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Timothy P. Clackson sold 59,369 shares of Ariad Pharmaceuticals stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $11.73, for a total transaction of $696,398.37. Following the sale, the insider now directly owns 288,141 shares of the company’s stock, valued at $3,379,893.93. The disclosure for this sale can be found here. Insiders own 8.20% of the company’s stock.
Ariad Pharmaceuticals Company Profile
ARIAD Pharmaceuticals, Inc (ARIAD) is an oncology company. The Company is focused on transforming the lives of cancer patients with medicines. The Company’s product pipeline includes Iclusig (ponatinib), brigatinib, AP32788 and ridaforolimus. The Company’s Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States, the European Union, Australia, Switzerland, Israel and Canada for the treatment of adult patients with chronic myeloid leukemia (CML), and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Want to see what other hedge funds are holding ARIA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ariad Pharmaceuticals Inc. (NASDAQ:ARIA).
Receive News & Ratings for Ariad Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ariad Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.